View ValuationKromek Group 将来の成長Future 基準チェック /06Kromek Groupの収益と利益はそれぞれ年間11.9%と134.7%減少すると予測されていますが、EPS は年間133.7% 減少すると予測されています。主要情報-134.7%収益成長率-133.71%EPS成長率Semiconductor 収益成長30.9%収益成長率-11.9%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日12 May 2026今後の成長に関する最新情報お知らせ • May 14Kromek Group plc Provides Earnings Guidance for the 12-Month Period Ended 30 April 2026Kromek Group plc provided earnings guidance for the 12-month period ended 30 April 2026. For the period, the company estimates to be revenues of £27.2 million in line with market expectations.お知らせ • Oct 28Kromek Group plc Provides earnings Guidance for the First Half of 2026Kromek Group plc provided earnings guidance for the first half of 2026. For the first half, the group expects to report revenue of at least £14.5m (H1 2025: £3.7m). This includes revenue generated under the Group's enablement agreement with Siemens Healthineers, as announced on 30 January 2025, of at least £8.2m (H1 2024: £nil). Accordingly, on an underlying basis, the Group expects to report revenue of at least £6.3m (H1 2025: £3.7m), representing growth of 70% over the first half of 2025. This was driven by strong growth in the CBRN Detection division as well as an increase in underlying revenue in the Advanced Imaging division.お知らせ • Sep 17Kromek Group plc Provides Earnings Guidance for the Fiscal Year 2026Kromek Group plc provided earnings guidance for the fiscal year 2026. For the year, the company expected to deliver further revenue growth and profitability, in line with market expectations.お知らせ • Jan 30Kromek Group plc Provides Earnings Guidance for the Year 2025Kromek Group plc provided earnings guidance for the year 2025. For the period, the Group expects to become profitable, with profit significantly ahead of market expectations. The Group also expects to achieve further revenue growth beyond Fiscal Year 2025 while delivering sustainable profits.すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Chairman Rakesh Sharma was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 14Kromek Group plc Provides Earnings Guidance for the 12-Month Period Ended 30 April 2026Kromek Group plc provided earnings guidance for the 12-month period ended 30 April 2026. For the period, the company estimates to be revenues of £27.2 million in line with market expectations.お知らせ • Dec 16Kromek Group plc to Report First Half, 2026 Results on Jan 20, 2026Kromek Group plc announced that they will report first half, 2026 results on Jan 20, 2026お知らせ • Oct 28Kromek Group plc Provides earnings Guidance for the First Half of 2026Kromek Group plc provided earnings guidance for the first half of 2026. For the first half, the group expects to report revenue of at least £14.5m (H1 2025: £3.7m). This includes revenue generated under the Group's enablement agreement with Siemens Healthineers, as announced on 30 January 2025, of at least £8.2m (H1 2024: £nil). Accordingly, on an underlying basis, the Group expects to report revenue of at least £6.3m (H1 2025: £3.7m), representing growth of 70% over the first half of 2025. This was driven by strong growth in the CBRN Detection division as well as an increase in underlying revenue in the Advanced Imaging division.お知らせ • Oct 03+ 1 more updateKromek Group plc, Annual General Meeting, Oct 27, 2025Kromek Group plc, Annual General Meeting, Oct 27, 2025. Location: kromek biosecurity boardroom, explorer 1 building, north east technology park netpark, thomas wright way, county durham ts21 3ff, sedgefield United Kingdomお知らせ • Sep 17Kromek Group plc Provides Earnings Guidance for the Fiscal Year 2026Kromek Group plc provided earnings guidance for the fiscal year 2026. For the year, the company expected to deliver further revenue growth and profitability, in line with market expectations.お知らせ • May 10+ 1 more updateKromek Group plc Announces CFO Changes, Effective 1 June 2025Kromek Group plc announced that Claire Burgess will be appointed as Chief Financial Officer ("CFO") of the Group, effective June 1, 2025. Claire Burgess has spent over 12 years in senior financial positions in businesses in the UK and US, primarily in the engineering and technology sectors. Most recently, Ms. Burgess was Financial Director of Advanced Electric Machines Group Ltd. ("AEM"), a designer and manufacturer of magnet-free electric powertrain technologies. Other experience includes being CFO of group companies JB Processing and TBGS Holdings and being responsible for establishing and building the US subsidiaries, including the acquisition of the Alabama White Marble Quarry. She is a qualified Fellow Chartered Accountant, having begun her career as an auditor at Ernst & Young before joining KPMG as a Corporate Finance Executive. Paul Farquhar is retiring and will therefore resign as CFO of the Group, effective June 1, 2025. Claire Burgess, aged 51, Current directorships and/or partnerships Former directorships and/or partnerships (within the last 5 years): Advanced Electric Machines Group Limited; Advanced Electric Machines Limited; Advanced Electric Machines Research Limited; Inn Collection (Bassenthwaite) Limited; Inn Collection Lakes (Ambleside) Limited; Inn Collection (Whitby) Limited; Inn Collection (Northallerton) Limited; Inn Collection (Helmsley) Limited; Inn Collection (Seaburn) Limited; Inn Collection Lakes (Coniston) Limited; Vindolanda Bidco Limited; Lindisfarne Inns Limited; Inn Collection Limited; Inn Collection AcquisitionCo Limited; Inn Collection Topco Limited; Inn Collection Midco Limited; Durham Vale Developments Limited; Vindolanda Midco 1 Limited; Marshall Inns Limited; Greensfield Moor Development Limited; Lindisfarne Inns (Bamburgh Castle) Limited; Inn Collection Bidco Limited; Vindolanda Topco Limited; Vindolanda Midco 2 Limited; Inn Collection Management Limited; and Inn Collection Lakes (Ambleside) Limited.お知らせ • Jan 30Kromek Group plc Provides Earnings Guidance for the Year 2025Kromek Group plc provided earnings guidance for the year 2025. For the period, the Group expects to become profitable, with profit significantly ahead of market expectations. The Group also expects to achieve further revenue growth beyond Fiscal Year 2025 while delivering sustainable profits.お知らせ • Nov 19Kromek Group plc, Annual General Meeting, Dec 13, 2024Kromek Group plc, Annual General Meeting, Dec 13, 2024. Location: kromek biosecurity boardroom, explorer 1 building, north east technology park netpark, thomas wright way, county durham, ts21 3ff, sedgefield United KingdomNew Risk • Nov 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£7.8m). Currently unprofitable and not forecast to become profitable next year (UK£3.4m net loss next year). Shareholders have been diluted in the past year (6.8% increase in shares outstanding). Market cap is less than US$100m (€50.6m market cap, or US$54.2m).Buy Or Sell Opportunity • Oct 29Now 24% overvaluedOver the last 90 days, the stock has fallen 1.5% to €0.066. The fair value is estimated to be €0.053, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 31% in a year. Earnings are forecast to decline by 3.2% in the next year.Reported Earnings • Oct 28Full year 2024 earnings released: UK£0.006 loss per share (vs UK£0.014 loss in FY 2023)Full year 2024 results: UK£0.006 loss per share (improved from UK£0.014 loss in FY 2023). Revenue: UK£19.4m (up 12% from FY 2023). Net loss: UK£3.29m (loss narrowed 46% from FY 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.New Risk • Aug 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended October 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported October 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£4.6m net loss next year). Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding). Market cap is less than US$100m (€41.0m market cap, or US$45.2m).Board Change • Mar 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Chris Wilks was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.業績と収益の成長予測DB:4KM - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数4/30/20273011824/30/202627216210/31/202538131317N/A7/31/20253281217N/A4/30/20252741116N/A1/31/202521-137N/A10/31/202416-6-6-1N/A7/31/202418-5-7-2N/A4/30/202419-3-8-3N/A1/31/202419-4-50N/A10/31/202318-4-33N/A7/31/202317-5-41N/A4/30/202317-6-50N/A1/31/202316-7-8-3N/A10/31/202214-8-11-5N/A7/31/202213-6-11-4N/A4/30/202212-5-10-4N/A1/31/202211-5-9-3N/A10/31/202110-5-8-2N/A7/31/202110-5-8-1N/A4/30/202110-5-7-1N/A1/31/202111-11-8-1N/A10/31/202012-17-9-1N/A7/31/202013-17-110N/A4/30/202013-17-120N/A1/31/202015-9-13-2N/A10/31/201916-1-13-4N/A7/31/201915-1N/A-4N/A4/30/201915-1N/A-5N/A1/31/201913-1N/A-5N/A10/31/201811-2N/A-5N/A7/31/201811-1N/A-5N/A4/30/201812-1N/A-5N/A1/31/201811-2N/A-4N/A10/31/201710-3N/A-4N/A7/31/20179-3N/A-3N/A4/30/20179-3N/A-1N/A1/31/20179-2N/A-1N/A10/31/20169-1N/A0N/A7/31/20169-2N/A-1N/A4/30/20168-2N/A-3N/A1/31/20168-2N/A-3N/A10/31/20158-3N/A-3N/A7/31/20158-2N/A-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 4KMの収益は今後 3 年間で減少すると予測されています (年間-134.7% )。収益対市場: 4KMの収益は今後 3 年間で減少すると予測されています (年間-134.7% )。高成長収益: 4KMの収益は今後 3 年間で減少すると予測されています。収益対市場: 4KMの収益は今後 3 年間で減少すると予想されています (年間-11.9% )。高い収益成長: 4KMの収益は今後 3 年間で減少すると予測されています (年間-11.9% )。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 4KMの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YSemiconductors 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 02:12終値2026/06/11 00:00収益2025/10/31年間収益2025/04/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kromek Group plc 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Michael MitchellCavendish
お知らせ • May 14Kromek Group plc Provides Earnings Guidance for the 12-Month Period Ended 30 April 2026Kromek Group plc provided earnings guidance for the 12-month period ended 30 April 2026. For the period, the company estimates to be revenues of £27.2 million in line with market expectations.
お知らせ • Oct 28Kromek Group plc Provides earnings Guidance for the First Half of 2026Kromek Group plc provided earnings guidance for the first half of 2026. For the first half, the group expects to report revenue of at least £14.5m (H1 2025: £3.7m). This includes revenue generated under the Group's enablement agreement with Siemens Healthineers, as announced on 30 January 2025, of at least £8.2m (H1 2024: £nil). Accordingly, on an underlying basis, the Group expects to report revenue of at least £6.3m (H1 2025: £3.7m), representing growth of 70% over the first half of 2025. This was driven by strong growth in the CBRN Detection division as well as an increase in underlying revenue in the Advanced Imaging division.
お知らせ • Sep 17Kromek Group plc Provides Earnings Guidance for the Fiscal Year 2026Kromek Group plc provided earnings guidance for the fiscal year 2026. For the year, the company expected to deliver further revenue growth and profitability, in line with market expectations.
お知らせ • Jan 30Kromek Group plc Provides Earnings Guidance for the Year 2025Kromek Group plc provided earnings guidance for the year 2025. For the period, the Group expects to become profitable, with profit significantly ahead of market expectations. The Group also expects to achieve further revenue growth beyond Fiscal Year 2025 while delivering sustainable profits.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Chairman Rakesh Sharma was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 14Kromek Group plc Provides Earnings Guidance for the 12-Month Period Ended 30 April 2026Kromek Group plc provided earnings guidance for the 12-month period ended 30 April 2026. For the period, the company estimates to be revenues of £27.2 million in line with market expectations.
お知らせ • Dec 16Kromek Group plc to Report First Half, 2026 Results on Jan 20, 2026Kromek Group plc announced that they will report first half, 2026 results on Jan 20, 2026
お知らせ • Oct 28Kromek Group plc Provides earnings Guidance for the First Half of 2026Kromek Group plc provided earnings guidance for the first half of 2026. For the first half, the group expects to report revenue of at least £14.5m (H1 2025: £3.7m). This includes revenue generated under the Group's enablement agreement with Siemens Healthineers, as announced on 30 January 2025, of at least £8.2m (H1 2024: £nil). Accordingly, on an underlying basis, the Group expects to report revenue of at least £6.3m (H1 2025: £3.7m), representing growth of 70% over the first half of 2025. This was driven by strong growth in the CBRN Detection division as well as an increase in underlying revenue in the Advanced Imaging division.
お知らせ • Oct 03+ 1 more updateKromek Group plc, Annual General Meeting, Oct 27, 2025Kromek Group plc, Annual General Meeting, Oct 27, 2025. Location: kromek biosecurity boardroom, explorer 1 building, north east technology park netpark, thomas wright way, county durham ts21 3ff, sedgefield United Kingdom
お知らせ • Sep 17Kromek Group plc Provides Earnings Guidance for the Fiscal Year 2026Kromek Group plc provided earnings guidance for the fiscal year 2026. For the year, the company expected to deliver further revenue growth and profitability, in line with market expectations.
お知らせ • May 10+ 1 more updateKromek Group plc Announces CFO Changes, Effective 1 June 2025Kromek Group plc announced that Claire Burgess will be appointed as Chief Financial Officer ("CFO") of the Group, effective June 1, 2025. Claire Burgess has spent over 12 years in senior financial positions in businesses in the UK and US, primarily in the engineering and technology sectors. Most recently, Ms. Burgess was Financial Director of Advanced Electric Machines Group Ltd. ("AEM"), a designer and manufacturer of magnet-free electric powertrain technologies. Other experience includes being CFO of group companies JB Processing and TBGS Holdings and being responsible for establishing and building the US subsidiaries, including the acquisition of the Alabama White Marble Quarry. She is a qualified Fellow Chartered Accountant, having begun her career as an auditor at Ernst & Young before joining KPMG as a Corporate Finance Executive. Paul Farquhar is retiring and will therefore resign as CFO of the Group, effective June 1, 2025. Claire Burgess, aged 51, Current directorships and/or partnerships Former directorships and/or partnerships (within the last 5 years): Advanced Electric Machines Group Limited; Advanced Electric Machines Limited; Advanced Electric Machines Research Limited; Inn Collection (Bassenthwaite) Limited; Inn Collection Lakes (Ambleside) Limited; Inn Collection (Whitby) Limited; Inn Collection (Northallerton) Limited; Inn Collection (Helmsley) Limited; Inn Collection (Seaburn) Limited; Inn Collection Lakes (Coniston) Limited; Vindolanda Bidco Limited; Lindisfarne Inns Limited; Inn Collection Limited; Inn Collection AcquisitionCo Limited; Inn Collection Topco Limited; Inn Collection Midco Limited; Durham Vale Developments Limited; Vindolanda Midco 1 Limited; Marshall Inns Limited; Greensfield Moor Development Limited; Lindisfarne Inns (Bamburgh Castle) Limited; Inn Collection Bidco Limited; Vindolanda Topco Limited; Vindolanda Midco 2 Limited; Inn Collection Management Limited; and Inn Collection Lakes (Ambleside) Limited.
お知らせ • Jan 30Kromek Group plc Provides Earnings Guidance for the Year 2025Kromek Group plc provided earnings guidance for the year 2025. For the period, the Group expects to become profitable, with profit significantly ahead of market expectations. The Group also expects to achieve further revenue growth beyond Fiscal Year 2025 while delivering sustainable profits.
お知らせ • Nov 19Kromek Group plc, Annual General Meeting, Dec 13, 2024Kromek Group plc, Annual General Meeting, Dec 13, 2024. Location: kromek biosecurity boardroom, explorer 1 building, north east technology park netpark, thomas wright way, county durham, ts21 3ff, sedgefield United Kingdom
New Risk • Nov 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£7.8m). Currently unprofitable and not forecast to become profitable next year (UK£3.4m net loss next year). Shareholders have been diluted in the past year (6.8% increase in shares outstanding). Market cap is less than US$100m (€50.6m market cap, or US$54.2m).
Buy Or Sell Opportunity • Oct 29Now 24% overvaluedOver the last 90 days, the stock has fallen 1.5% to €0.066. The fair value is estimated to be €0.053, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 31% in a year. Earnings are forecast to decline by 3.2% in the next year.
Reported Earnings • Oct 28Full year 2024 earnings released: UK£0.006 loss per share (vs UK£0.014 loss in FY 2023)Full year 2024 results: UK£0.006 loss per share (improved from UK£0.014 loss in FY 2023). Revenue: UK£19.4m (up 12% from FY 2023). Net loss: UK£3.29m (loss narrowed 46% from FY 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
New Risk • Aug 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended October 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported October 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£4.6m net loss next year). Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding). Market cap is less than US$100m (€41.0m market cap, or US$45.2m).
Board Change • Mar 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Chris Wilks was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.